Russell Investments Group’s Acrivon Therapeutics ACRV Stock Holding History

Russell Investments Group’s Portfolio ACRV Stock Details ACRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$669	Hold	481	–	–	﹤0.01%	4090
2025 Q4	$1.16K	Hold	481	–	–	﹤0.01%	4042
2025 Q3	$871	Hold	481	–	–	﹤0.01%	4053
2025 Q2	$572	Buy	+481	New	+$660	﹤0.01%	3733
2025 Q1	–	Sell	-223	Closed	-$1.34K	–	3791
2024 Q4	$1.34K	Sell	223 -35	-14%	-$254	﹤0.01%	3499
2024 Q3	$1.81K	Sell	258 -911	-78%	-$7.18K	﹤0.01%	3393
2024 Q2	$6.78K	Buy	1,169 +946	+424%	+$7.62K	﹤0.01%	3156
2024 Q1	$1.59K	Buy	+223	New	+$1.03K	﹤0.01%	3096

Other funds holding ACRV

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Russell Investments Group's ACRV Position: Q1 2026 in Review

Russell Investments Group held its Acrivon Therapeutics (ACRV) position steady in Q1 2026 at 481 shares worth $669. The position accounts for ﹤0.01% of the portfolio, ranked #4090.

Russell Investments Group first reported a position in ACRV in Q1 2024 and has held it in 8 quarters since. The position peaked at $6.78K in Q2 2024. 44 funds tracked by Wall St. Rank hold ACRV as of Q1 2026.

Russell Investments Group held 481 shares of Acrivon Therapeutics worth $669 as of Q1 2026.
Russell Investments Group left its Acrivon Therapeutics share count unchanged in Q1 2026.
Acrivon Therapeutics made up ﹤0.01% of Russell Investments Group's portfolio in Q1 2026, its #4090 holding.
Russell Investments Group first reported a position in Acrivon Therapeutics in Q1 2024 and has held it in 8 quarters since.
Russell Investments Group's Acrivon Therapeutics position peaked at $6.78K in Q2 2024.
44 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q1 2026.

Based on Russell Investments Group's 13F filing for Q1 2026, filed 8 May 2026.